O

Obio Technology Shanghai Corp Ltd
SSE:688238

Watchlist Manager
Obio Technology Shanghai Corp Ltd
SSE:688238
Watchlist
Price: 5.48 CNY -6.16% Market Closed
Market Cap: 3.5B CNY
Have any thoughts about
Obio Technology Shanghai Corp Ltd?
Write Note

Obio Technology Shanghai Corp Ltd
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Obio Technology Shanghai Corp Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
O
Obio Technology Shanghai Corp Ltd
SSE:688238
Total Current Liabilities
ÂĄ314.2m
CAGR 3-Years
63%
CAGR 5-Years
32%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Total Current Liabilities
ÂĄ13.6B
CAGR 3-Years
10%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Total Current Liabilities
ÂĄ3.9B
CAGR 3-Years
16%
CAGR 5-Years
22%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Total Current Liabilities
ÂĄ6.8B
CAGR 3-Years
8%
CAGR 5-Years
38%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Total Current Liabilities
ÂĄ5.3B
CAGR 3-Years
46%
CAGR 5-Years
37%
CAGR 10-Years
31%
W
WuXi XDC Cayman Inc
HKEX:2268
Total Current Liabilities
ÂĄ1.3B
CAGR 3-Years
241%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Obio Technology Shanghai Corp Ltd
Glance View

Market Cap
3.5B CNY
Industry
Life Sciences Tools & Services

Obio Technology Shanghai Corp. Ltd. engages in biomedical basic research, gene therapy drug incubation, and clinical grade gene therapy virus vector CDMO service provision. The company is headquartered in Shanghai, Shanghai and currently employs 631 full-time employees. The company went IPO on 2022-03-22. The firm is mainly engaged in providing contract research organization (CRO) services such as gene therapy vector development and gene function research for the basic research of gene therapy, as well as contract research and development production organization (CDMO) services such as pharmaceutical research and clinical sample production for the research and development of gene drugs. The firm mainly conducts business in the European and American markets and the domestic market.

Intrinsic Value
4.5 CNY
Overvaluation 18%
Intrinsic Value
Price
O

See Also

What is Obio Technology Shanghai Corp Ltd's Total Current Liabilities?
Total Current Liabilities
314.2m CNY

Based on the financial report for Dec 31, 2023, Obio Technology Shanghai Corp Ltd's Total Current Liabilities amounts to 314.2m CNY.

What is Obio Technology Shanghai Corp Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
32%

Over the last year, the Total Current Liabilities growth was 68%. The average annual Total Current Liabilities growth rates for Obio Technology Shanghai Corp Ltd have been 63% over the past three years , 32% over the past five years .

Back to Top